

**University of Texas Health Science Center at San Antonio  
Institutional Biosafety Committee (IBC)  
Microsoft Teams MINUTES OF MEETING  
June 10, 2025**

**Members attending the meeting:** Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Gould, Georgianna; Ginsburg, Brett; Mishra, Bibhuti; Paukert, Martin; Salamango, Daniel; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Bloodworth, Rebecca; Macias, Dorothy (alternate for Charlton, Michael - voting)

**Guests Present:** Melendez, Griselda; Barlett, Emily; Vasquez, Rebecca; Colby, Angelique.

**Absent members:** Charlton, Michael; Dallas, Steven; Elliott, James; Gauduin, Marie Claire; Ko, Jisook; Martinez-Sobrido, Luis; Prewit, Egle; Xiang, Yan; Yeh, Chih-Ko.

**1. Panel Chair Announcement**

The meeting was called to order at 11:00 a.m. by the IBC Co-Chair, Dr. Tiffani Burgin. A quorum was established.

**2. Confidentiality of Panel Proceedings and Conflict of Interest**

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

**3. Approval of minutes from the previous meeting**

The Committee approved the minutes as written from the May 13, 2025, IBC meeting.

**Approved** (13 voted to approve, 0 opposed, 0 abstained)

**4. Review of Approved Protocols-** The spreadsheet of approved protocols will be sent out for review in August 2025.

**5. Old Business – None**

**6. Educational Items – None**

**7. Occupational Medicine- None**

**8. Other – Discussion on the current DURC policy and PI survey.**

## 9. Review of EHS Assistant-

## 10. Meeting Reminder

The next meeting will be held on July 08, 2025.

### Protocols for Review

#### 11. Presentation, Discussion, and Voting on an Initial Protocol:

**Protocol ID:** 0000019621

**Principal Investigator:** Svatek, Robert; Urology

**Title:** N/A

**Review Type:** Full Committee Review

**Form Type:** Initial

#### **Under Review by IBC Committee Members.**

Initial application, to expand their work with Cretostimogene to patients who are unresponsive to BCG at BSL-2 containment.

*Protocol does not include the use of recombinant DNA.*

This protocol was approved with clarification.

1. The committee members requested additional information on the protocol.

*NIH Guidelines:*

*Administration of recombinant or synthetic nucleic acid molecules into humans III-C*

#### 12. Presentation, Discussion, and Voting on an Amendment Protocol:

**Protocol ID:** 0000019799

**Principal Investigator:** Shapiro, Mark; Cellular & Integrative Physiology

**Title:** None

**Review Type:** Full Review

**Form Type:** Amendment

**Approved** (13 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with human serum at BSL-2 containment.

*Protocol does include the use of recombinant DNA.*

This protocol was approved with clarification.

1. The committee members requested additional information on downstream experiments.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

### **13. Presentation, Discussion, and Voting on an Initial Protocol:**

**Protocol ID:** 0000019626

**Principal Investigator:** Maselli Caceres, Diego; Medicine/ Division of Pulmonary Diseases and Critical Care.

**Title:** Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGenR 10.3)

**Review Type:** Full Review

**Form Type:** Initial

**Approved** (13 voted to approve, 0 opposed, 0 abstained)

Initial application, to work with human blood and Plasma at BSL-2 containment.

*Protocol does not include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

### **14. Presentation, Discussion, and Voting on an Amendment Protocol:**

**Protocol ID:** 0000019840

**Principal Investigator:** Goldberg, Mark; Neurology

**Title:** None

**Review Type:** Full Review

**Form Type:** Amendment

**Approved** (13 voted to approve, 0 opposed, 0 abstained)

Amendment application, to work with human plasma at BSL-2 containment.

*Protocol does include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

**15. Presentation, Discussion, and Voting on an Amendment Protocol:****Protocol ID:** 0000019734**Principal Investigator:** Lawrenson-Gayther, Kate; Obstetrics/Gynecology**Title:** None**Review Type:** Full Review**Form Type:** Amendment**Approved** (13 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with iPSC Pancreatic, iPSC Breast, iPSC Prostate, and FT283 organoids at BSL-2 containment.

In vivo:

Work with iPSC Pancreatic, iPSC Breast, iPSC Prostate, and FT283 organoids in Immunocompromised mice at ABSL-1 containment.

IACUC# IPROTO202500000042

*Protocol does include the use of recombinant DNA.*

This protocol was approved with clarification.

1. The committee members requested additional information on the source of iPSC's.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

*Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2*

*Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1*

*Cloning and vector construction in bacteria and yeasts. III-E, III-F*

*Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F*

*Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

*Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4*

**16. Presentation, Discussion, and Voting on an Amendment Protocol:****Protocol ID:** 0000019789**Principal Investigator:** Bieniek, Kevin; Alzheimer's Neurodegenerative Institute**Title:** None**Review Type:** Full Review**Form Type:** Amendment**Approved** (13 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Drosophila fruit flies at BSL-1 containment.

Work with knock-out mice strain P2RY12 cKO and transgenic mice APP-SAA and rTg4510 at ABSL-1 containment. IACUC# 0220072AP, #IAMEND202500000171

*Protocol does not include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*


*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*


*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

*Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4*

Adjourn: The meeting adjourned at 12:03 P.M.

---

  
Dr. Tiffani Burgin  
Institutional Biosafety Committee Co-Chair  
University of Texas Health San Antonio

  
Dorothy Macias  
Recorder, Institutional Biosafety Committee  
University of Texas Health San Antonio

dam